Table 1.
ELISA Categories | Negative (n=40) | Intermediate (n=20) | P Value | Strongly Positive (n=36) | P Value |
---|---|---|---|---|---|
ELISA values, mean; median | |||||
Endoglin | 1058; 992 | 6486; 6357 | <0.001 | 37,432; 26,101 | <0.001 |
FLT3 | 1311; 1105 | 5499; 5876 | <0.001 | 29,876; 19,104 | <0.001 |
EDIL3 | 324; 0 | 4437; 4397 | <0.001 | 34,213; 23,290 | <0.001 |
ICAM4 | 3215; 3272 | 15,378; 13,077 | <0.001 | 56,839; 32,896 | <0.001 |
Recipient age (yr), mean±SD | 52±16 | 49±13 | 0.47 | 47±15 | 0.22 |
Race, % not white | 40 | 40 | >0.99 | 50 | 0.49 |
Men, % | 25 | 50 | 0.08 | 44 | 0.09 |
Previous transplantation, % | 40 | 50 | 0.58 | 39 | >0.99 |
HLA sensitization,a % | 90 | 90 | >0.99 | 97 | 0.36 |
Mean CPRAb (CDC-XM, FCXM), % | 27, 37 | 27, 38 | 0.94 | 35, 44 | 0.48 |
Original ABO or HLA barrier,c % | |||||
ABOi | 10 | 15 | 0.68 | 18 | 0.50 |
CDC-XM+ | 2 | 0 | >0.99 | 6 | 0.60 |
FCXM+ | 15 | 15 | >0.99 | 19 | 0.76 |
FCXM−, DSA+ | 48 | 55 | 0.78 | 50 | >0.99 |
No DSA | 35 | 30 | 0.78 | 25 | 0.45 |
Donor, mean age (yr)±SD | 38±13 | 43±12 | 0.12 | 42±16 | 0.25 |
Live donor, % | 45 | 55 | 42 | ||
Deceased donor, % | 55 | 45 | 0.59 | 58 | 0.82 |
HLA-A;B;DR;DQ mismatch, mean±SD | 4.7±2.3 | 4.1±2.7 | 0.41 | 5.2±1.5 | 0.21 |
Plasmapheresis treatments | |||||
No pre- or post-treatments, % | 50 | 35 | 0.41 | 42 | 0.50 |
Pretransplant, mean, median | 1.0, 0.0 | 1, 1 | 0.67 | 0.5, 0.0 | 0.17 |
Post-transplant, mean, median | 3.6, 1.0 | 3, 2 | 0.86 | 4.5, 2.0 | 0.54 |
Anti-CD25 induction, % | 17 | 20 | >0.99 | 15 | 0.76 |
Thymoglobulin induction, % | 83 | 80 | >0.99 | 85 | 0.76 |
Rituximab induction, % | 33 | 45 | 0.40 | 38 | 0.63 |
CPRA, calculated panel reactive antibody; CDC-XM, cytotoxicity crossmatch; ABO, blood group antigen; ABOi, blood group incompatible; DSA, donor HLA-specific antibody; HLA-A;B;DR;DQ, histocompatibility antigens.
HLA-specific antibody detected on Luminex bead immunoassays.
CPRA was determined for HLA antibodies of sufficient strength to yield a positive CDC-XM or FCXM.
Original donor HLA-specific antibody (DSA) strength before desensitization treatment.